883 related articles for article (PubMed ID: 25783747)
21. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
22. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
23. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
[TBL] [Abstract][Full Text] [Related]
24. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
[TBL] [Abstract][Full Text] [Related]
25. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304
[TBL] [Abstract][Full Text] [Related]
26. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
27. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
[TBL] [Abstract][Full Text] [Related]
28. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
29. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
[TBL] [Abstract][Full Text] [Related]
30. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
31. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
Terzi NK; Yilmaz I; Oz AB
Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
[TBL] [Abstract][Full Text] [Related]
32. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
34. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
35. World Health Organization grade II-III astrocytomas consist of genetically distinct tumor lineages.
Hattori N; Hirose Y; Sasaki H; Nakae S; Hayashi S; Ohba S; Adachi K; Hayashi T; Nishiyama Y; Hasegawa M; Abe M
Cancer Sci; 2016 Aug; 107(8):1159-64. PubMed ID: 27196377
[TBL] [Abstract][Full Text] [Related]
36. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
37. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC
Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485
[TBL] [Abstract][Full Text] [Related]
38. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.
Ren X; Cui X; Lin S; Wang J; Jiang Z; Sui D; Li J; Wang Z
PLoS One; 2012; 7(3):e32764. PubMed ID: 22427879
[TBL] [Abstract][Full Text] [Related]
39. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
40. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]